Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Double-blind, Cross-Over Study to Compare the Capacity to Prevent Follicular Rupture of CDB-2914 With Placebo, When Administered After the Ovulatory Process Has Been Triggered by the LH Surge

NCT01107093 is registered in ClinicalTrials.gov with HRA Pharma as lead sponsor.

NCT NCT01107093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01107093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Double-blind, Cross-Over Study to Compare the Capacity to Prevent Follicular Rupture of CDB-2914 With Placebo, When Administered After the Ovulatory Process Has Been Triggered by the LH Surge
Lead sponsor
HRA Pharma
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2008
Completion date
December 31, 2008
Enrollment
35 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

contraception